Linked Life Data

15328815

Source:http://linkedlifedata.com/resource/pubmed/id/15328815

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2004-8-26
pubmed:abstractText
Opioids are associated with a number of adverse effects, constipation being the most common long-term adverse effect in patients with advanced cancer. Significant progress has been made over the past several decades in understanding the mechanisms of action of opioid compounds; however, these advances have yielded few new treatments for the bowel dysfunction caused by opioids. Methylnaltrexone, the first peripheral opioid receptor antagonist and currently under clinical investigation, has the potential to prevent or treat opioid-induced peripherally mediated side effects, such as constipation, without interfering with analgesia. This article reviews existing clinical data on methylnaltrexone, focusing on the antagonism of opioid-induced adverse effects in the gut.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1544-6794
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
111-7; discussion 119-22
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:articleTitle
Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effects.
pubmed:affiliation
Department of Anesthesia & Critical Care, Pritzker School of Medicine, The University of Chicago, 5841 S. Maryland Avenue, MC 4028, Chicago, IL 60637, USA. cyuan@airway.uchicago.edu
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Review